Dicerna Pharmaceuticals, Inc. (DRNA)

Check out top investors' recommendation for DRNA
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
22.67
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
100%/0%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for liver diseases and cancers based on a proprietary RNA interference technology platform in the United States and internationally. The company?s development programs include DCR-PH1 for the treatment of primary hyperoxaluria 1 (PH1) through targeting the liver metabolic enzyme glycolate oxidase; and other rare inherited diseases involving disease target genes expressed in the liver, including maple syrup urine disease, familial amyloid polyneuropathy or cardiomyopathy, alpha-1 anti-trypsin hepatocyte inclusions, hemophilia A and B, paroxysmal nocturnal hemoglobinuria, and others. It is also developing DCR-M1711 for the treatment of various cancers through targeting the MYC oncogene, a gene that causes or promotes cancer when abnormally expressed or activated; and a product candidate targeting the oncogene KRAS. The company has a research collaboration and license agreement with Kyowa Hakko Kirin Co., Ltd. for the research, development, and commercialization of DsiRNA molecules and drug delivery technologies for therapeutic targets in oncology; and a license agreement with City of Hope, an academic research and medical center, to manufacture, use, offer for sale, sell, and import products related to DsiRNA for the prevention and treatment of various diseases in humans. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Watertown, Massachusetts.
Sector:
Industry:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Robyn Karnauskas Deutsche Bank Securities Buy   Sep 13, '18     27.00  Sep 13, '19  N/A 
Edward Nash Cowen And Company Buy   Sep 06, '18     20.00  Sep 06, '19  N/A 
Ed Arce Mcnicoll, Lewis, & Vlak Buy   Aug 15, '18     21.00  Aug 15, '19  N/A 
Ritu Baral Canaccord Genuity Buy   Aug 09, '18       Aug 09, '19  N/A 
Ritu Baral Canaccord Genuity Buy   Apr 11, '18       Apr 11, '19  N/A 
Stephen Willey Stifel Nicolaus & Company, Inc. Buy   Mar 09, '18     17.00  Mar 09, '19  N/A 
Edward Nash Cowen And Company Buy   Feb 05, '18     13.00  Feb 05, '19  N/A 
Ed Arce Mcnicoll, Lewis, & Vlak Buy   Nov 03, '17     10.00  Nov 03, '18  N/A 
Ed Arce Mcnicoll, Lewis, & Vlak Buy   Aug 11, '17     6.00  Aug 11, '18  N/A 
Ritu Baral Canaccord Genuity Buy   Jul 18, '17       Jul 18, '18  N/A 
Ed Arce Mcnicoll, Lewis, & Vlak Buy   May 23, '17     5.00  May 23, '18  N/A 
Ritu Baral Canaccord Genuity Buy   Mar 31, '17       Mar 31, '18  N/A 
Michael Schmidt Leerink Swann Llc Buy   Dec 22, '15   12.28  20.00  Dec 22, '16  -75.16% 
Stephen Willey Stifel Nicolaus & Company, Inc. Buy   Nov 11, '15   11.95  20.00  Nov 11, '16  -70.88% 
Ritu Baral Canaccord Genuity Buy   Sep 08, '15   11.19    Sep 08, '16  N/A 
Thomas Wei Jefferies & Co. Buy   May 29, '15   16.54  25.00  May 29, '16  -77.51% 
Michael Schmidt Leerink Swann Llc Buy   Mar 13, '15   25.13    Mar 13, '16  -78.23%